GlycoMimetics Inc (GLYC)
0.2716
0.00 (0.00%)
USD |
NASDAQ |
May 31, 16:00
0.2711
0.00 (0.00%)
After-Hours: 20:00
GlycoMimetics Free Cash Flow (Quarterly): -10.52M for March 31, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -10.52M |
December 31, 2023 | -7.616M |
September 30, 2023 | -8.691M |
June 30, 2023 | -6.985M |
March 31, 2023 | -11.61M |
December 31, 2022 | -7.912M |
September 30, 2022 | -8.620M |
June 30, 2022 | -16.27M |
March 31, 2022 | -13.74M |
December 31, 2021 | -12.81M |
September 30, 2021 | -16.95M |
June 30, 2021 | -13.62M |
March 31, 2021 | -14.13M |
December 31, 2020 | -9.724M |
September 30, 2020 | -11.52M |
June 30, 2020 | -14.56M |
March 31, 2020 | -3.508M |
December 31, 2019 | -12.81M |
September 30, 2019 | -13.47M |
June 30, 2019 | -11.47M |
March 31, 2019 | -14.39M |
December 31, 2018 | -10.04M |
September 30, 2018 | -10.11M |
Date | Value |
---|---|
June 30, 2018 | -13.08M |
March 31, 2018 | -10.23M |
December 31, 2017 | -8.403M |
September 30, 2017 | -6.263M |
June 30, 2017 | -6.272M |
March 31, 2017 | -9.125M |
December 31, 2016 | -6.393M |
September 30, 2016 | -7.697M |
June 30, 2016 | -7.098M |
March 31, 2016 | -9.247M |
December 31, 2015 | -6.961M |
September 30, 2015 | 13.51M |
June 30, 2015 | -6.348M |
March 31, 2015 | -8.707M |
December 31, 2014 | -6.169M |
September 30, 2014 | -4.856M |
June 30, 2014 | 9.132M |
March 31, 2014 | -2.601M |
December 31, 2013 | -5.578M |
September 30, 2013 | -3.428M |
June 30, 2013 | -2.731M |
March 31, 2013 | -3.883M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-16.95M
Minimum
Sep 2021
-3.508M
Maximum
Mar 2020
-11.33M
Average
-11.56M
Median
Free Cash Flow (Quarterly) Benchmarks
Altimmune Inc | -16.36M |
Lyell Immunopharma Inc | -42.05M |
Amicus Therapeutics Inc | -31.51M |
InfuSystems Holdings Inc | -1.298M |
Nanoviricides Inc | -1.988M |